Related Experiment Video

Updated: May 24, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Anticoagulation therapy. Dabigatran and risk of myocardial infarction

John W Eikelboom1, Jeffrey I Weitz

  • 1Thrombosis and Atherosclerosis Research Institute, McMaster University, 237 Barton Street East, Hamilton, Ontario, Canada.

Nature Reviews. Cardiology
|March 14, 2012
PubMed

Insights

Dabigatran use may increase acute coronary events compared to warfarin, according to recent trials and a meta-analysis. This review examines the evidence and discusses patient care implications.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Dabigatran is a direct thrombin inhibitor used for anticoagulation.
  • Previous randomized trials have suggested a potential link between dabigatran and acute coronary events.
  • A recent meta-analysis by Uchino and Hernandez further investigated this association.

Purpose of the Study:

  • To critically review the existing evidence associating dabigatran with an increased risk of acute coronary events.
  • To analyze the findings of recent randomized trials and meta-analyses on this topic.
  • To discuss the clinical implications of these findings for patient management and care.

Main Methods:

  • Systematic review and critical appraisal of published randomized controlled trials.
  • Meta-analysis data from Uchino and Hernandez were considered.
  • Evidence synthesis to evaluate the association between dabigatran and acute coronary events.

Main Results:

  • Multiple randomized trials and a recent meta-analysis indicate a potential increase in acute coronary events with dabigatran compared to warfarin.
  • The strength and consistency of this association across studies are evaluated.
  • Specific patient populations or risk factors may be identified.

Conclusions:

  • The association between dabigatran and increased acute coronary events warrants careful consideration.
  • Clinicians should weigh the risks and benefits of dabigatran, particularly in patients with a history of coronary artery disease.
  • Further research may be needed to clarify the mechanisms and clinical significance of this finding.

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...